Answers are grounded in this paper and cite their sources.
Examines inflammatory mediators in pneumonia models, suggesting improved treatment strategies.
Pneumonia is one of the most common and serious infections afflicting humans. In the United States, pneumonia affects 3 million adults each year, resulting in 500,000 hospital admissions and 45,000 deaths (Anonymous 1997). Pneumonia remains the sixth most common cause of death overall and the most common cause of death from an infectious disease in the United States, and its mortality rate has increased since 1980 (Anonymous 1988; Garibaldi 1985; Pinner and others 1996). The increasing proportion of older individuals in industrialized countries, as well as growing numbers of immunocompromised patients worldwide, has resulted in a large population that is particularly susceptible to pneumonia. In addition, widespread use of antibiotics has led to increasing antibiotic resistance among the causative pathogens, producing infections that are difficult to treat and have a poorer outcome (Doernl995; Holmberg and others 1987). In this context, modulation of the host immune response as an adjunctive treatment of pneumonia presents a tantalizing prospect. The rationale for this approach stems from clinical observations of increased incidence and severity of pneumonia in diverse populations of immunocompromised hosts (Sanders and Crystal 1997). These observations are confirmed by animal studies that have shown the feasibility of altering the outcome of pneumonia by specific augmentation or depletion of inflammatory mediators. Translation of such interventions in animal models to treatment of patients requires a thorough understanding of the normal host response to various pathogens in pneumonia.
No takes yet. Share an insight, caveat, or question.
Mehrad et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: